On September 11, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its investigational anti-PD-1 antibody tislelizumab, its investigational BTK inhibitor zanubrutinib, and its investigational PARP inhibitor pamiparib, will be presented in seven oral presentations and four poster presentations at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China (Press release, BeiGene, SEP 11, 2019, View Source [SID1234539469]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentations:

Title: Tislelizumab in Chinese Patients with Non-Small Cell Lung
Cancer (NSCLC) and Nasopharyngeal Carcinoma (NPC)
Session: Lung Cancer Session 1
Date: Thursday, September 19
Time: 11:20 – 11:25
Location Auditorium, Level 1
Presenter Qing Zhou, M.D., Ph.D., Guangdong Provincial People’s Hospital

Title: Tislelizumab for Relapsed/Refractory Classical Hodgkin
Lymphoma: Updated Follow-up Efficacy and Safety Results
from a Phase 2 Study
Session: Innovative Drug Clinical Data Session 1
Date: Thursday, September 19
Time: 14:30 – 14:40
Location Strait Hall, Level 2
Presenter: Yuqin Song, M.D., Ph.D., Beijing Cancer Hospital

Title: Tislelizumab in Chinese Patients with Melanoma, Urothelial
Carcinoma (UC), and Renal Cell Carcinoma (RCC)
Session: Kidney Cancer Session 4
Date: Thursday, September 19
Time: 16:35 – 16:40
Location Conference Room 2A, Level 2
Presenter: Lili Mao, M.D., Ph.D. Beijing Cancer Hospital

Title: Tislelizumab in Chinese Patients with Esophageal Cancer
(EC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC),
and Microsatellite Instability-High/Mismatch Repair Deficient
(MSI-H/dMMR) Tumors
Session: Advanced Gastric Cancer Session 3
Date: Friday, September 20
Time: 11:24 – 11:36
Location Banquet Hall 1, Level 2
Presenter: Lin Shen, M.D., Ph.D., Beijing Cancer Hospital

Title: Safety and Efficacy in Patients with Long-Term Exposure
(LTE) to Tislelizumab, an Investigational Anti-PD-1 Antibody,
in a First-in-Human Phase 1 Study
Session: Immuno-Oncology Session 3
Date: Friday, September 20
Time: 11:54 – 12:00
Location Hall 1G, Level 1
Presenter Chia-Jui Yen, M.D., Ph.D., National Cheng Kung University Hospital

Title: Tislelizumab Plus Chemotherapy as First-Line Treatment for
Chinese Patients with Lung Cancer
Session: Lung Cancer Session 3
Date: Saturday, September 21
Time: 11:38 – 11:44
Location Auditorium, Level 1
Presenter: Zhijie Wang, M.D., Ph.D., Cancer Hospital, Chinese Academy of Medical Sciences

Title: Tislelizumab in Combination with Chemotherapy as
Treatment for Chinese Patients with Esophageal Squamous
Cell Carcinoma (ESCC)
Session: Innovative Drug Clinical Data Session 1
Date: Saturday, September 21
Time: 14:30 – 14:40
Location Banquet Hall 2, Level 2
Presenter: Ru Jia, M.D., The Fifth Medical Center, General Hospital of the People’s Liberation Army

Poster Presentations:

Title: Dose Escalation of Pamiparib in Chinese Patients with High-
Grade Non-Mucinous Ovarian Cancer (HGOC) or Advanced
Triple-Negative Breast Cancer (TNBC)
Board #: P-36
Date: Thursday, September 19
Time: Afternoon
Location: Strait Hall Poster Area, Level 2
Presenter: Xiyan Mu, M.D., BeiGene

Title: Zanubrutinib for Patients with Relapsed or Refractory
Chronic Lymphocytic Leukemia or Small Lymphocytic
Lymphoma
Board #: P-45
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Meng Ji, M.D., BeiGene

Title: Zanubrutinib, a Highly Specific BTK Inhibitor in Chinese
Patients with Relapsed/Refractory B-cell Malignancies:
Follow-up Report of a Phase 1 Trial in China
Board #: P-46
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Chenmu Du, M.D., BeiGene

Title: The molecular binding mechanism of tislelizumab, an
investigational anti-PD-1 antibody, is differentiated from
pembrolizumab and nivolumab
Board #: P-60
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Ye Liu, Ph.D., BeiGene